Drug Trial News

RSS

Sequella broadens the licensed therapeutic indications of its SQ109 lead drug candidate

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat life-threatening infectious diseases, today announced that it amended an existing agreement with the National Institutes of Health (NIH) to significantly broaden the licensed therapeutic indications, or "field of use," for Sequella's lead drug candidate, SQ109.

16 Nov 2009

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.

16 Nov 2009

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Seattle Genetics, Inc. today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology.

16 Nov 2009

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).

16 Nov 2009

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

Aradigm Corporation today announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis.

16 Nov 2009

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

16 Nov 2009

Aspirin doses have beneficial effects for patients with heart diorders: Study

On Sunday, November 15, 2009, Florida Atlantic University (FAU) researcher Charles H. Hennekens, M.D., the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Biomedical Science will present at the American Heart Association's Annual Scientific Sessions meeting in Orlando, FL, the first data in humans to show that all doses of aspirin used in clinical practice increase nitric oxide.

16 Nov 2009

New reversible blood thinner for angioplasty patients not superior over placebo

A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Phase I clinical study for ETC-1002 commenced

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.

16 Nov 2009

Axelar AB to present data from ongoing Phase I/II clinical trial of AXL1717

Axelar AB today announced that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor, will be presented next week at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, USA.

13 Nov 2009

Findings on the use of Traumeel S in children with mucositis undergoing SCT presented

New research findings presented today at the Society for Integrative Oncology's (SIO) Sixth International Conference in New York show promise in assessing the efficacy and safety of complementary and alternative medicine (CAM) using traditional research methods.

13 Nov 2009

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.

13 Nov 2009

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.

13 Nov 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia.

13 Nov 2009

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Lexicon Pharmaceuticals, Inc. announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS).

13 Nov 2009

Adolor commences clinical testing of its oral mu opioid receptor antagonist

Adolor Corporation today announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in healthy volunteers will assess safety and tolerability of the compound and will be followed by a multiple ascending dose study in early 2010.

13 Nov 2009

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Senesco Technologies, Inc. announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference.

12 Nov 2009

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.

12 Nov 2009

Tobira Therapeutics presents data on TBR-652 at the European AIDS Conference

Tobira Therapeutics, a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two double-blind, placebo-controlled studies of TBR-652 in eighty-four healthy volunteers.

12 Nov 2009

Drug Trial News

Sequella broadens the licensed therapeutic indications of its SQ109 lead drug candidate

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Aspirin doses have beneficial effects for patients with heart diorders: Study

New reversible blood thinner for angioplasty patients not superior over placebo

Phase I clinical study for ETC-1002 commenced

Axelar AB to present data from ongoing Phase I/II clinical trial of AXL1717

Findings on the use of Traumeel S in children with mucositis undergoing SCT presented

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Adolor commences clinical testing of its oral mu opioid receptor antagonist

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

Tobira Therapeutics presents data on TBR-652 at the European AIDS Conference

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News